<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00125944</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP125</org_study_id>
    <nct_id>NCT00125944</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults</brief_title>
  <official_title>A Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <brief_summary>
    <textblock>
      The objective is to assess the safety of bivalent vaccine of two new 6:2 influenza virus
      reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist)
      containing them.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date>January 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint of this study is fever (Study Days 0-7), defined as oral temperature of at least ³101°F.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reported Reactogenocity Events (REs) and Adverse Events (AEs) that occur within 7 days after vaccination and that occur within 14 days after vaccination. SAEs and SNMCs that occur within 28 days after vaccination and within 180 days</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Healthy</condition>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FluMist</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females, 18 to 49 years of age (not yet reached their 50th birthday) at the
             time of study vaccination

          -  Healthy by medical history and health assessment

          -  Sexually active females, unless surgically sterile or at least 1 year post-menopausal,
             must have used an effective method of avoiding pregnancy (including oral, implanted,
             injectable, or transdermal contraceptives, intrauterine device [IUD], female condom,
             diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual
             partner or sterile sexual partner) for at least 30 days prior to study vaccination,
             and must agree to continue using such precautions for at least 90 days after study
             vaccination; the volunteer must also have a negative serum or urine pregnancy test
             within 14 days prior to study vaccination (if screening and study vaccination do not
             occur on the same day) and on the day of study vaccination prior to randomization

          -  Sexually active males, unless surgically sterile, must use an effective method of
             birth control (condom or abstinence) and must agree to continue using such precautions
             for at least 30 days after study vaccination

          -  Available by telephone

          -  Written informed consent (and Health Insurance Portability and Accountability Act
             [HIPAA] authorization if applicable) obtained from the participant

          -  Ability to understand and comply with the requirements of the protocol, as judged by
             the investigator

          -  Ability to complete follow-up period of 180 days after study vaccination, as required
             by the protocol

        Exclusion Criteria:

          -  History of hypersensitivity of any component of the vaccine, including egg or egg
             protein

          -  History of hypersensitivity to gentamicin

          -  Any condition for which the inactivated influenza vaccine is indicated, including
             chronic disorders of the pulmonary or cardiovascular systems (e.g., asthma); chronic
             metabolic diseases (e.g., diabetes mellitus); renal dysfunction; or hemoglobinopathies
             that required regular medical follow-up or hospitalization during the preceding year.

          -  Acute febrile (&gt;100.0°F oral or equivalent) and/or clinically significant respiratory
             illness (e.g., cough or sore throat) within the 14 days prior to randomization

          -  Any known immunosuppressive condition or immune deficiency disease, including HIV
             infection, or ongoing immunosuppressive therapy

          -  History of Guillain-Barré syndrome

          -  Household contact who is immunocompromised (participant should also avoid close
             contact with immunocompromised individuals for at least 21 days post study
             vaccination)

          -  Receipt of any investigational agent within 30 days prior to enrollment, or expected
             receipt through 180 days after study vaccination (use of licensed agents for
             indications not listed in the package insert is permitted)

          -  Chronic or regular use of anti-pyretic or analgesic medication on a daily or every
             other day basis.

        Note: A daily dose of 81 mg of aspirin is not considered a contraindication to enrollment.
        Discontinuation of prophylactic use of anti-pyretic or analgesic medications at the time of
        enrollment and for 14 days following vaccination is not considered a contraindication to
        enrollment.

          -  Administration of intranasal medications within 14 days prior to randomization, or
             expected receipt through 14 days after study vaccination

          -  Nursing mother

          -  Employee of the research center, any individual involved with the conduct of the
             study, or any family member of such individuals

          -  Any condition that, in the opinion of the investigator, would interfere with
             evaluation of the vaccine or interpretation of study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Walker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radiant Research, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research, Daytona Beach</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Discoveries, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2005</study_first_submitted>
  <study_first_submitted_qc>August 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2005</study_first_posted>
  <last_update_submitted>May 8, 2007</last_update_submitted>
  <last_update_submitted_qc>May 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

